The Chronic Myelomonocytic Leukemia (CMML) drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Myelomonocytic Leukemia (CMML), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Myelomonocytic Leukemia (CMML). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Myelomonocytic Leukemia (CMML) and features dormant and discontinued products.

GlobalData tracks 71 drugs in development for Chronic Myelomonocytic Leukemia (CMML) by 58 companies/universities/institutes. The top development phase for Chronic Myelomonocytic Leukemia (CMML) is phase i with 29 drugs in that stage. The Chronic Myelomonocytic Leukemia (CMML) pipeline has 68 drugs in development by companies and three by universities/ institutes. Some of the companies in the Chronic Myelomonocytic Leukemia (CMML) pipeline products market are: Bristol-Myers Squibb, Novartis and Ascentage Pharma Group International.

The key targets in the Chronic Myelomonocytic Leukemia (CMML) pipeline products market include DNA (Cytosine 5 ) Methyltransferase 1 (CXXC Type Zinc Finger Protein 9 or DNA Methyltransferase HsaI or MCMT or DNMT1 or EC 2.1.1.37), Apoptosis Regulator Bcl 2 (Protein Phosphatase 1 Regulatory Subunit 50 or BCL2), and Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1).

The key mechanisms of action in the Chronic Myelomonocytic Leukemia (CMML) pipeline product include DNA (Cytosine 5 ) Methyltransferase 1 (CXXC Type Zinc Finger Protein 9 or DNA Methyltransferase HsaI or MCMT or DNMT1 or EC 2.1.1.37) Inhibitor with seven drugs in Phase III. The Chronic Myelomonocytic Leukemia (CMML) pipeline products include seven routes of administration with the top ROA being Oral and seven key molecule types in the Chronic Myelomonocytic Leukemia (CMML) pipeline products market including Small Molecule, and Monoclonal Antibody.

Chronic Myelomonocytic Leukemia (CMML) overview

Chronic Myelomonocytic Leukemia (CMML) is a type of rare blood cancer that combines features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It primarily affects the bone marrow and blood cells, resulting in the overproduction of abnormal monocytes (a type of white blood cell) and other blood cells. CMML is characterized by an increased number of monocytes in the blood and bone marrow, along with varying degrees of abnormal changes in other blood cell types. This disease is typically diagnosed in older adults and can have a range of symptoms or may be asymptomatic in some cases. The symptoms of CMML can include fatigue, weakness, recurrent infections, fever, enlarged spleen or liver, easy bruising or bleeding, and night sweats. However, some individuals might not exhibit any symptoms during the early stages of the disease.

For a complete picture of Chronic Myelomonocytic Leukemia (CMML)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.